£50.0M
NRG Therapeutics raises £50m in Series B funding to advance mitochondrial drugs into clinical trials
The financing round was led by SV Health Investors and will fund initial human trials for the company lead candidate in ALS and Parkinson's.
"Developing new drugs to treat neurological diseases is very challenging, but is receiving increased interest given the high unmet medical need and growing prevalence in ageing populations."
